A detailed history of Alpha Centric Advisors LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 30,000 shares of EXAS stock, worth $1.62 Million. This represents 1.73% of its overall portfolio holdings.

Number of Shares
30,000
Previous 30,000 -0.0%
Holding current value
$1.62 Million
Previous $1.27 Million 61.17%
% of portfolio
1.73%
Previous 1.05%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

BUY
$41.33 - $74.26 $41,330 - $74,260
1,000 Added 3.45%
30,000 $1.27 Million
Q1 2024

Apr 24, 2024

BUY
$56.27 - $73.77 $1.63 Million - $2.14 Million
29,000 New
29,000 $2 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.54B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.